/Companies

Breye Therapeutics

9 known investors

Find your way into Breye Therapeutics

Sign up to see every warm intro you have to Breye Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Breye Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Breye Therapeutics is a biopharmaceutical company developing medicines for ophthalmologic and metabolic diseases, leveraging expertise in clinical development, manufacturing, and regulatory pathways. The company focuses on bringing novel therapies from early-stage discovery through late-stage development and product approval.

Founders & leadership

UM
Ulrik MouritzenCEO

Investors · 9

Also in the syndicate · 3

EIFOInnovestor Life ScienceLjungström family office

Funding

SEC filings, press & company announcements

$67.5M disclosed across 1 round · 2026

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Frequently asked questions

What does Breye Therapeutics do?
Breye Therapeutics is a biopharmaceutical company developing medicines for ophthalmologic and metabolic diseases, leveraging expertise in clinical development, manufacturing, and regulatory pathways. The company focuses on bringing novel therapies from early-stage discovery through late-stage development and product approval.
Who are Breye Therapeutics's investors?
Breye Therapeutics's investors include Novo Holdings, Modi Ventures, Sound Bioventures, Catalyze Capital, Mission Biocapital, Pappas Capital.
How much funding has Breye Therapeutics raised?
Breye Therapeutics has disclosed $67.5M raised across 1 round.